Opus Genetics (IRD) 10-Q 2 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 02, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Entity Registrant Name	REXAHN PHARMACEUTICALS, INC.
Entity Central Index Key	1,228,627
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	rnn
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		37,521,170

Condensed Balance Sheet

Condensed Balance Sheet - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 4,591,722	$ 8,899,154
Marketable securities	7,974,010	17,931,941
Prepaid expenses and other current assets	1,154,898	1,304,541
Total Current Assets	13,720,630	28,135,636
Security Deposits	30,785	30,785
Equipment, Net	123,480	121,460
Total Assets	13,874,895	28,287,881
Current Liabilities:
Accounts payable and accrued expenses	3,331,646	3,233,926
Deferred Research and Development Arrangement		375,000
Other Liabilities	29,850	56,724
Warrant Liabilities	4,101,504	7,853,635
Total Liabilities	7,463,000	11,519,285
Commitments and Contingencies (note 14)
Stockholders' Equity:
Preferred stock, par value $0.0001, 10,000,000 authorized shares, none issued and outstanding
Common stock, par value $0.0001, 75,000,000 and 50,000,000 authorized shares, 31,751,939 and 31,725,114 issued and outstanding	3,175	3,173
Additional paid-in capital	158,008,879	157,141,021
Accumulated other comprehensive loss	(29,487)	(56,886)
Accumulated deficit	(151,570,672)	(140,318,712)
Total Stockholders' Equity	6,411,895	16,768,596
Total Liabilities and Stockholders' Equity	$ 13,874,895	$ 28,287,881

Condensed Balance Sheet (Parent

Condensed Balance Sheet (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Condensed Balance Sheet [Abstract]
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	75,000,000	50,000,000
Common Stock, Shares, Issued	31,751,939	31,725,114
Common Stock, Shares, Outstanding	31,751,939	31,725,114

Condensed Statement Of Operatio

Condensed Statement Of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Statement Of Operations [Abstract]
Revenues:
Expenses:
General and administrative	1,795,952	1,574,323	5,192,122	5,004,832
Research and development	2,887,955	2,644,999	10,379,081	7,451,656
Total Expenses	4,683,907	4,219,322	15,571,203	12,456,488
Loss from Operations	(4,683,907)	(4,219,322)	(15,571,203)	(12,456,488)
Other Income (Expense)
Interest income	55,153	60,750	198,362	135,329
Other income			368,750
Unrealized (loss) gain on fair value of warrants	(710,065)	3,120,500	3,752,131	(9,047,831)
Financing expense				(333,050)
Total Other Income (Expense)	(654,912)	3,181,250	4,319,243	(9,245,552)
Net Loss Before Provision for Income	(5,338,819)	(1,038,072)	(11,251,960)	(21,702,040)
Provision for income taxes
Net Loss	$ (5,338,819)	$ (1,038,072)	$ (11,251,960)	$ (21,702,040)
Net loss per share, basic and diluted	$ (0.17)	$ (0.04)	$ (0.35)	$ (0.83)
Weighted average number of shares outstanding, basic and diluted	31,751,450	28,459,316	31,742,531	26,121,160

Condensed Statement Of Comprehe

Condensed Statement Of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Condensed Statement Of Comprehensive Loss [Abstract]
Net Loss	$ (5,338,819)	$ (1,038,072)	$ (11,251,960)	$ (21,702,040)
Unrealized gain (loss) on available-for-sale securities	35,468	11,740	27,399	(7,843)
Comprehensive Loss	$ (5,303,351)	$ (1,026,332)	$ (11,224,561)	$ (21,709,883)

Condensed Statement Of Cash Flo

Condensed Statement Of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows from Operating Activities:
Net loss	$ (11,251,960)	$ (21,702,040)
Adjustments to reconcile net loss to net cash used in operating activities:
Compensatory stock	22,650	31,200
Depreciation and amortization	37,204	30,963
Amortization of premiums and discounts on marketable securities, net	35,110	40,578
Stock-based compensation	845,210	790,006
Amortization and termination of deferred research and development arrangement	(375,000)	(56,250)
Unrealized (gain) loss on fair value of warrants	(3,752,131)	9,047,831
Financing expense		333,050
Amortization of deferred lease incentive	(9,332)	(9,333)
Deferred lease expenses	(17,542)	(8,314)
Changes in assets and liabilities:
Prepaid expenses and other assets	149,643	(669,087)
Accounts payable and accrued expenses	97,720	456,277
Net Cash Used in Operating Activities	(14,218,428)	(11,715,119)
Cash Flows from Investing Activities:
Purchase of equipment	(39,224)	(21,369)
Purchase of marketable securities		(15,008,660)
Redemption of marketable securities	9,950,220	8,720,000
Net Cash Provided by (Used In) Investing Activities	9,910,996	(6,310,029)
Cash Flows from Financing Activities:
Issuance of common stock and units, net of issuance costs		9,241,271
Proceeds from exercise of stock warrants		5,354,093
Proceeds from exercise of stock options		77,500
Net Cash Provided by Financing Activities		14,672,864
Net Decrease in Cash and Cash Equivalents	(4,307,432)	(3,352,284)
Cash and Cash Equivalents - beginning of period	8,899,154	11,578,473
Cash and Cash Equivalents - end of period	$ 4,591,722	8,226,189
Non-cash financing and investing activties:
Warrants issued		4,107,488
Warrant liability extinguishment from exercise of warrants		$ 8,052,594

Operations And Organization

Operations And Organization	9 Months Ended
	Sep. 30, 2018
Operations And Organization [Abstract]
Operations And Organization	1. Operations and Organization Operations Rexahn Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biopharmaceutical company whose principal operations are the discovery and development of innovative treatments for cancer.  Liquidity and Going Concern Accounting Standards Codification (“ASC”) 205-40 , Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASC 205-40”) , requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.  As of September 30, 2018, the Company had cash, cash equivalents and marketable securities of approximately $12.6 million, working capital of approximately $10. 4 million and an accumulated deficit of approximately $151. 6 million, and anticipates incurring losses through fiscal year 2018 and beyond. The Company has incurred negative cash flow from operations since inception and not yet generated commercial revenues. The Company believes that its cash, cash equivalents, and marketable s ecurities at September 30, 2018 and the proceeds received from its completed registered direct public offering in October 2018, will be sufficient to fund current operations through the third quarter of 2019 and that the Company would require additional capital to fund operations beyond that point. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements are issued. To meet its needs, the Company intends to raise additional capital through equity financings, collaborations, or partnerships. Under ASC 205-40 , management’s plans must be approved before the date the financial statements are issued to be considered probable of being effectively implemented, and the future receipt of potential funding is not considered probable at this time because none of the Company’s current plans have been finalized at the time of filing this Quarterly Report on Form 10-Q. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of September 30, 2018 and December 31, 2017 and of the results of operations, and comprehensive loss for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017 have been included. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of results that may be expected for any other interim period or the full fiscal year ending December 31, 2018. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Form 10-K”). Information included in the condensed balance sheet as of December 31, 2017 has been derived from the Company’s audited financial statements for the year ended December 31, 2017 included in the 2017 Form 10-K. The unaudited condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.  Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Actual results may ultimately differ from these estimates. These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available. 

Recent Accounting Pronouncement

Recent Accounting Pronouncements Affecting the Company	9 Months Ended
	Sep. 30, 2018
Recent Accounting Pronouncements Affecting the Company [Abstract]
Recent Accounting Pronouncements Affecting the Company	2. Recent Accounting Pronouncements Affecting the Company Revenue from Contracts with Customers  In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers,” a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company should recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services and provides a revenue recognition framework in accordance with this principle. On August 12, 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 by one year to December 15, 2017 for annual reporting periods beginning after that date and interim periods therein. The Company adopted this guidance for the quarterly reporting period ended March 31, 2018, using the modified retrospective method. As the Company does not have revenue contracts, the adoption of this guidance did not have a material impact on the operating results of the Company, there were no significant changes to disclosures, and there was no cumulative adjustment to the opening balance of retained earnings as of January 1, 2018.  Leases  In February 2016, the FASB issued ASU 2016-02, “Leases,” which requires an entity to recognize assets and liabilities arising from leases on the balance sheet and to provide additional disclosures about leasing arrangements. ASU 2016-02 will be effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact the adoption of this guidance will have on its financial statements.   

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2018
Marketable Securities [Abstract]
Marketable Securities	 3. Marketable Securities  Marketable securities are considered “available-for-sale” in accordance with FASB Accounting Standards Codification (“ASC”) 320, “Debt and Equity Securities,” and thus are reported at fair value in the Company’s accompanying balance sheet, with unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity. Amounts reclassified out of accumulated other comprehensive income (loss) into realized gains and losses are accounted for on the basis of specific identification and are included in other income or expense in the statement of operations. The Company classifies such investments as current on the balance sheet as the investments are readily marketable and available for use in current operations.  The following table shows the Company’s marketable securities’ adjusted cost, gross unrealized gains and losses, and fair value by significant investment category as of September 30, 2018 and December 31, 2017:    September 30, 2018  Cost Gross Unrealized Gross Unrealized Fair  Basis Gains Losses Value  Corporate Bonds $ 8,003,497 $ - $ (29,487) $ 7,974,010   December 31, 2017  Cost Gross Unrealized Gross Unrealized Fair  Basis Gains Losses Value  Commercial Paper $ 3,241,005 $ - $ (2,505) $ 3,238,500  Corporate Bonds 14,747,822 - (54,381) 14,693,441  Total Marketable Securities $ 17,988,827 $ - $ (56,886) $ 17,931,941  The Company typically invests in highly-rated securities, with the primary objective of minimizing the potential risk of principal loss. As of September 30, 2018, the Company had six corporate bonds with an aggregate fair value of $ 5,974,460 and unrealized losses of $ 26,899 that have been unrealized losses for less than 12 months, and two corporate bonds with an aggregate fair value of $ 1,999,550 and unrealized losses of $ 2,588 that have been unrealized losses for greater than 12 months. The Company does not intend to sell its marketable securities in an unrealized loss position. Based upon these securities’ fair value relative to the cost, high ratings, and volatility of fair value, the Company considers the declines in market value of its marketable securities to be temporary in nature, does not consider any of its investments other-than-temporarily impaired, and anticipates that it will recover the entire amortized cost basis.  As of September 30, 2018, all of the Company’s marketable securities are due to mature in less than one year.

Prepaid Expenses And Other Curr

Prepaid Expenses And Other Current Assets	9 Months Ended
	Sep. 30, 2018
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid Expenses And Other Current Assets	4. Prepaid Expenses and Other Current Assets     September 30, December 31,  2018 2017   Deposits on contracts $ 520,677 $ 793,940  Prepaid expenses and other current assets 634,221 510,601   $ 1,154,898 $ 1,304,541 Deposits on contracts consist of deposits on research and development contracts for services that had not been incurred as of the balance sheet date. Prepaid expenses and other assets include prepaid general and administrative expenses, such as insurance, rent, investor relations fees and compensatory stock issued for services not yet incurred as of the balance sheet date.

Equipment, Net

Equipment, Net	9 Months Ended
	Sep. 30, 2018
Equipment, Net [Abstract]
Equipment, Net	5. Equipment, Net     September 30, December 31,  2018 2017   Furniture and fixtures $ 82,686 $ 82,686  Office and computer equipment 159,489 171,724  Lab equipment 447,653 445,134  Leasehold improvements 131,762 133,762   Total equipment 821,590 833,306  Less: Accumulated depreciation and amortization (698,110) (711,846)   Net carrying amount $ 123,480 $ 121,460

Accounts Payable And Accrued Ex

Accounts Payable And Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Accounts Payable And Accrued Expenses [Abstract]
Accounts Payable And Accrued Expenses	6. Accounts Payable and Accrued Expenses      September 30, December 31,  2018 2017   Trade payables $ 1,298,168 $ 895,638  Accrued expenses 103,000 95,416  Accrued research and development contract costs 1,252,445 1,435,109  Payroll liabilities 678,033 807,763   $ 3,331,646 $ 3,233,926 

Deferred Research And Developme

Deferred Research And Development Arrangement	9 Months Ended
	Sep. 30, 2018
Deferred Research And Development Arrangement [Abstract]
Deferred Research And Development Arrangement	7. Deferred Research and Development Arrangement Rexgene Biotech Co., Ltd. In 2003, the Company entered into a collaborative research agreement with Rexgene Biotech Co., Ltd. (“Rexgene”), a stockholder. Rexgene agreed to assist the Company with the research, development and clinical trials necessary for registration of the Company’s drug candidate RX-0201 (Archexin®) in Asia. In accordance with the agreement, Rexgene paid the Company a one-time fee of $ 1, 500,000 in 2003. The agreement provided that it would expire upon the later of (i) 20 years after the date of the agreement or (ii) the expiration of the patents relating to RX-0201. The amortization reduced research and development expenses for the periods presented. The payment from Rexgene was used in the cooperative funding of the costs of development of RX-0201.  On February 5, 2018, the Company and NEXT BT Co. Ltd., (“Next BT”) the successor in interest to Rexgene, terminated the agreement. In exchange for Next BT terminating its rights to RX-0201 in Asia, the Company agreed to pay Next BT a royalty in the low single digits of any net sales of RX-0201 the Company makes in Asia and 50% of the Company’s licensing revenue related to the licensing of RX-0201 in Asia, up to an aggregate of $5,000,000 . Upon termination of the agreement, the unamortized deferred research and development arrangement liability of $368,750 was eliminated and recognized as other income. The Company historically used 20 years as its basis for recognition and accordingly, for the nine months ended September 30, 2018, research and development expenses were reduced by $6,250 for the period beginning January 1, 2018 up to the agreement’s termination. For the three and nine months ended September 30, 2017, $18,750 and $56,250 , respectively was reduced from research and development expenses. 

Other Liabilities

Other Liabilities	9 Months Ended
	Sep. 30, 2018
Other Liabilities [Abstract]
Other Liabilities	8. Other Liabilities  Deferred Lease Incentive  In accordance with the Company’s office lease agreement, as amended and further discussed in Note 14, the Company has been granted leasehold improvement allowances from the lessor to be used for the construction cost of improvements to the leased property, which included architectural and engineering fees, government agency plan check, permit and other fees, sales and use taxes, testing and inspection costs and telephone and data cabling and wiring in the premises. The Company accounted for the benefit of the leasehold improvement allowance as a reduction of rental expense over the term of the office lease. The following table sets forth the cumulative deferred lease incentive:     September 30, December 31,  2018 2017   Deferred lease incentive $ 154,660 $ 154,660  Less accumulated amortization (145,327) (135,995)   Balance $ 9,333 $ 18,665 Deferred Office Lease Expense The lease agreement, as amended, provided for an initial annual base rent with annual increases over the lease term. The Company recognizes rental expense on a straight-line basis over the term of the lease, which resulted in a deferred rent liability of $20,517 and $38,059 as of September 30, 2018 and December 31, 2017, respectively.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2018
Net Loss Per Common Share [Abstract]
Net Loss Per Common Share	9. Net Loss per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding, plus the number of common share equivalents that would be dilutive. As of September 30, 2018, and December 31, 2017, there were stock options, restricted stock units and warrants to acquire, in the aggregate , 9, 534,122 and 8,961,140 shares of the Company’s common stock, respectively, that are potentially dilutive. However diluted loss per share is the same as basic loss per share for all periods presented because the inclusion of common share equivalents would be anti-dilutive.

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2018
Common Stock [Abstract]
Common Stock	10. Common Stock The following transactions occurred during the nine months ended September 30, 2018:  Authorized Shares On August 30, 2018, the Company’s shareholders approved an increase in the Company’s authorized shares of stock from 50,000,000 to 75,000,000.  Compensatory Shares During the nine months ended September 30, 2018, the Company issued 15,000 shares to a privately held investor relations firm in exchange for investor relations services. The aggregate market value of the stock issued was $22,650 .  Restricted Stock Units During the nine months ended September 30, 2018, the Company issued 11,825 shares resulting from the vesting of restricted stock units (“RSUs”). 

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2018
Stock-Based Compensation [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation As of September 30, 2018, the Company had 2, 599,038 options to purchase common stock and 35,475 RSUs outstanding. At the Company’s Annual Meeting of Shareholders held on June 10, 2013, the Company’s shareholders voted to approve the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (the “2013 Plan”). Under the 2013 Plan, the Company grants equity awards to key employees, directors and consultants of the Company. At the Company’s Annual Meeting held on June 9, 2016, the Company’s shareholders voted to approve an amendment and restatement of the 2013 Plan, including to provide for awards of restricted stoc k and restricted stock units. The Company initially reserved 1,700,000 shares of common stock for issuance pursuant to the 2013 Plan, and on April 11, 2017, the Company’s shareholders approved an increase of 1,700,000 shares of common stock reserved for issuance pursuant to the 2013 Plan. As of September 30, 2018, there were 2, 287,038 options and 35,475 RSUs outstanding under the 2013 Plan, and 1, 064,912 shares were available for issuance. On August 5, 2003, the Company established a stock option plan (the “2003 Plan”). Under the 2003 Plan, the Company granted stock options to key employees, directors and consultants of the Company. With the adoption of the 2013 Plan, no new stock options may be issued under the 2003 Plan, but previously issued options under the 2003 Plan remain outstanding until their expiration. As of September 30, 2018, there were 300,000 options outstanding under the 2003 Plan. In March 2016, the Company granted to a third party an option to purchase up to 12,000 shares of the Company’s common stock. These were the only Company stock options outstanding as of September 30, 2018 that were not issued pursuant to the 2013 Plan or the 2003 Plan. Accounting for Awards Stock-based compensation expense is the estimated fair value of options and RSUs granted amortized on a straight-line basis over the requisite vesting service period for the entire portion of the award. Total stock-based compensation recognized by the Company for the three and nine months ended September 30, 2018 and 2017 is as follows:    For the Three Months Ended September 30, For the Nine Months Ended September 30,  2018 2017 2018 2017  Statement of operations line item:  General and administrative $ 188,920 $ 184,914 $ 579,924 $ 580,812  Research and development 92,562 42,700 265,286 209,194   Total $ 281,482 $ 227,614 $ 845,210 $ 790,006 No income tax benefit has been recognized in the statement of operations for stock-based compensation arrangements as the Company has provided for a 100 % valuation allowance on its deferred tax assets. Summary of Stock Option Transactions There were 8 60,307 stock options granted at exercise prices ranging from $1. 46 to $2.29 with an aggregate fair value of $ 1,089,851 during the nine months ended September 30, 2018. There were 483,260 stock options granted at exercise prices ranging from $1.84 to $6.18 with an aggregate fair value of $ 738,937 during the nine months ended September 30, 2017. For the majority of the grants to employees, the vesting period is 25% on the first anniversary of the grant date and, thereafter, one thirty-sixth of the remaining option vests in equal installments on the first business day of each month until fully vested. Options generally expire ten years from the date of grant. For the majority of grants to non-employee consultants of the Company, the vesting period is between one and three years, subject to the fulfillment of certain conditions in the individual stock agreements, or 100% upon the occurrence of certain events specified in the individual stock agreements. The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The Company took into consideration guidance under ASC 718, “Compensation-Stock Compensation,” and Staff Accounting Bulletin No. 107 (“SAB 107”) when reviewing and updating assumptions. The expected volatility is based upon historical volatility of the Company’s stock. The expected term is based upon the simplified method as allowed under SAB 107.  The assumptions made in calculating the fair values of options are as follows:     Nine Months Ended September 30,  2018 2017  Black-Scholes assumptions  Expected dividend yield 0 % 0 %  Expected volatility 69-72 % 69-79 %  Risk-free interest rate 2.3 -2.8 % 1.8 -2.0 %  Expected term (in years) 5.5 -6 years 5.5 -6 years A summary of stock option activity for the nine months ended September 30, 2018 is as follows:     Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value  Outstanding, January 1, 2018 1,814,231 $ 5.33 7.1 years $ 53,883  Granted 860,307 $ 1.96  Exercised - $ -  Expired (25,000) $ 21.78  Cancelled (50,500) $ 5.16   Outstanding, September 30, 2018 2,599,038 $ 4.06 7.5 years $ 50,870  Exercisable, September 30, 2018 1,345,721 $ 5.71 6.1 years $ -    There were no stock options exercised during the three and nine months ended September 30, 2018 or for the three months ended September 30, 2017. The total intrinsic value of options exercised was $97,872 for the nine months ended September 30, 2017. The weighted average fair value of the options granted was $1.27 and $ 1.53 for the nine months ended September 30, 2018 and 2017, respectively. A summary of the Company’s unvested options as of September 30, 2018 and changes during the nine months ended September 30, 2018 is presented below:     2018  Number of Options Weighted Average Fair Value at Grant Date  Unvested at January 1, 2018 727,543 $ 2.39  Granted 860,307 $ 1.27  Vested (334,533) $ 2.89  Cancelled - $ -   Unvested at September 30, 2018 1,253,317 $ 1.49 As of September 30, 2018, there was $ 1,494,158 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average vesting period of 2. 5 years. Summary of Restricted Stock Unit Transactions The Company began granting RSUs to employees in 2017. The fair value of an RSU award is the closing price of the Company’s common stock on the date of grant. A summary of RSU activity for the nine months ended September 30, 2018 is as follows:    Number of RSUs Weighted Average Grant Date Fair Value  Outstanding, January 1, 2018 47,300 $ 1.84  Granted - $ -  Vested and Released (11,825) $ 1.84  Cancelled - $ -   Outstanding, September 30, 2018 35,475 $ 1.84 As of September 30, 2018, there was $51, 512 of total unrecognized compensation cost related to unvested RSUs which is expected to be recognized over a weighted average vesting period of 2. 4 years.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2018
Warrants [Abstract]
Warrants	12. Warrants As of September 30, 2018, warrants to purchase up to 6,899,609 shares were outstanding, having exercise prices ranging from $ 2.85 to $ 12. 80 and expiration dates ranging from October 16, 2018 to April 17, 20 23 .     2018 2017  Number of warrants Weighted average exercise price Number of warrants Weighted average exercise price  Balance, January 1 7,099,609 $ 4.55 5,452,691 $ 4.92  Issued during the period - $ - 1,696,970 $ 4.01  Exercised during the period - $ - (1,861,195) $ 3.51  Expired during the period (200,000) $ 5.90 - $ -   Balance, September 30 6,899,609 $ 4.51 5,288,466 $ 5.13 At September 30, 2018, the weighted average remaining contractual life of the outstanding warrants was 3. 4 years.  The warrants issued to investors in the November 2015, March 2016 and September 2016 offerings contain a provision for net cash settlement in the event of a fundamental transaction (contractually defined to include a merger, sale of substantially all assets, tender offer or share exchange). Pursuant to the November 2015, March 2016, and September 2016 warrants, if a fundamental transaction occurs, then the warrant holder has the option to receive cash, equal to the fair value of the remaining unexercised portion of the warrant. The June 2017 and October 2017 warrants contain a provision that allows the holder to opt for cash settlement in a fundamental transaction that was approved by, or required to be approved by, the board of directors of the Company. All of the Company’s outstanding warrants provide the holder the option as to the type of consideration received if the holders of common stock receive an option as to their consideration. In addition, all of the Company’s outstanding warrants contain a cashless exercise provision that is exercisable only in the event that a registration statement is not effective. That provision may not be operative if an effective registration statement is not available because an exemption under the U.S. securities laws may not be available to issue unregistered shares. As a result, net cash settlement may be required, and the warrants require liability classification.  ASC 820, “Fair Value Measurements and Disclosures,” provides requirements for disclosure of liabilities that are measured at fair value on a recurring basis in periods subsequent to the initial recognition. Fair values for warrants were determined using the Binomial Lattice (“Lattice”) valuation technique. The Lattice model provides for dynamic assumptions regarding volatility and risk-free interest rates within the total period to maturity. Accordingly, within the contractual term, the Company provided multiple date intervals over which multiple volatilities and risk-free interest rates were used. These intervals allow the Lattice model to project outcomes along specific paths that consider volatilities and risk-free rates that would be more likely in an early exercise scenario.  Significant assumptions are determined as follows: Trading market values —Published trading market values; Exercise price —Stated exercise price; Term —Remaining contractual term of the warrant; Volatility —Historical trading volatility for periods consistent with the remaining terms; and Risk-free rate —Yields on zero coupon government securities with remaining terms consistent with the remaining terms of the warrants.  Due to the fundamental transaction provision, which could provide for early redemption of the warrants, the model also considered the probability the Company would enter into a fundamental transaction during the remaining term of the warrant. Because the Company is not yet achieving positive cash flow, management believes the probability of a fundamental transaction occurring over the term of the warrant is unlikely and therefore estimates the probability of entering into a fundamental transaction to be 5 %. For valuation purposes, the Company also assumed that if such a transaction did occur, it was more likely to occur towards the end of the term of the warrants.  The significant unobservable inputs used in the fair value measurement of the warrants include management’s estimate of the probability that a fundamental transaction may occur in the future. Significant increases (decreases) in the probability of occurrence would result in a significantly higher (lower) fair value measurement. The following table summarizes the fair value of the warrants as of the respective balance sheet dates:     Fair Value as of:  Warrant Issuance: September 30, 2018 December 31, 2017  July 2013 Investor Warrants $ - $ 8,762  October 2013 Investor Warrants - 26,288  January 2014 Investor Warrants - 29,257  November 2015 Investor Warrants 399,278 1,260,050  November 2015 Placement Agent Warrants 591 2,936  March 2016 Investor Warrants 296,462 697,554  September 2016 Investor Warrants 592,513 1,054,083  June 2017 Investor Warrants 1,059,522 1,981,864  June 2017 Placement Agent Warrants 115,769 221,591  October 2017 Investor Warrants 1,476,646 2,305,552  October 2017 Placement Agent Warrants 160,723 265,698  Total: $ 4,101,504 $ 7,853,635 The following table summarizes the number of shares indexed to the warrants as of the respective balance sheet dates:     Number of Shares indexed as of:  Warrant Issuance September 30, 2018 December 31, 2017  July 2013 Investor Warrants - 200,000  October 2013 Investor Warrants 231,732 231,732  January 2014 Investor Warrants 476,193 476,193  November 2015 Investor Warrants 1,250,001 1,250,001  November 2015 Placement Agent Warrants 3,334 3,334  March 2016 Investor Warrants 607,806 607,806  September 2016 Investor Warrants 805,000 805,000  June 2017 Investor Warrants 1,515,152 1,515,152  June 2017 Placement Agent Warrants 181,818 181,818  October 2017 Investor Warrants 1,632,654 1,632,654  October 2017 Placement Agent Warrants 195,919 195,919  Total: 6,899,609 7,099,609 The assumptions used in calculating the fair values of the warrants are as follows:     September 30, 2018 December 31, 2017  Trading market prices $ 1.78 $ 2.02  Estimated future volatility 101 % 104 %  Dividend - -  Estimated future risk-free rate 3.02 -3.04 % 2.14 -2.45 %  Equivalent volatility 49-76 % 85-104 %  Equivalent risk-free rate 1.10 -2.70 % 1.30 -1.89 %    Changes in the fair value of the warrant liabilities, carried at fair value, reported as “unrealized (loss) gain on fair value of warrants” in the statement of operations:     For the Three Months Ended September 30, For the Nine Months Ended September 30,  2018 2017 2018 2017  Expired and Fully Exercised Warrants $ - $ 7,306 $ - $ (855,010)  July 2013 Investor Warrants - 125,686 8,762 (55,362)  October 2013 Investor Warrants - 135,683 26,288 (102,608)  January 2014 Investor Warrants - 177,900 29,257 (125,148)  November 2015 Investor Warrants 5,971 797,688 860,772 (1,304,350)  November 2015 Placement Agent Warrants 211 1,691 2,345 (366,694)  March 2016 Investor Warrants (38,943) 356,472 401,092 (2,873,309)  September 2016 Investor Warrants (109,915) 506,353 461,570 (4,807,246)  June 2017 Investor Warrants (178,869) 894,076 922,342 1,277,485  June 2017 Placement Agent Warrants (22,518) 117,645 105,822 164,411  October 2017 Investor Warrants (331,671) - 828,906 -  October 2017 Placement Agent Warrants (34,331) - 104,975 -  Total: $ (710,065) $ 3,120,500 $ 3,752,131 $ (9,047,831) 

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Taxes [Abstract]
Income Taxes	13. Income Taxes No provision for federal and state income taxes was required for the three and nine months ended September 30, 2018 and 2017 due to the Company’s operating losses and increased deferred tax asset valuation allowance. At September 30, 2018 and December 31, 2017, the Company had unused net operating loss carry-forwards of approximately $142,488,000 and $ 127,877 ,000 respectively. Some of this amount may be subject to annual limitations under certain provisions of the Internal Revenue Code related to “changes in ownership.” As of September 30, 2018 and December 31, 2017, the deferred tax assets related to the aforementioned carry-forwards have been fully offset by valuation allowances, because significant utilization of such amounts is not presently expected in the foreseeable future. Deferred tax assets and valuation allowances consist of:     September 30, December 31,  2018 2017   Net Operating Loss Carryforwards $ 39,897,000 $ 35,805,000  Stock Compensation Expense 1,558,000 1,458,000  Book tax differences on assets and liabilities 209,000 365,000  Valuation Allowance (41,664,000) (37,628,000)   Net Deferred Tax Assets $ - $ - The Company files income tax returns in the U.S. federal and Maryland state jurisdictions. Tax years for fiscal 2015 through 2017 are open and potentially subject to examination by the federal and Maryland state taxing authorities.

Commitments And Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies [Abstract]
Commitments And Contingencies	14. Commitments and Contingencies a) The Company has contracted with various vendors for services, with terms that require payments over the terms of the agreements, usually ranging from two to 36 months. The costs to be incurred are estimated and are subject to revision. As of September 30, 2018, the total estimated cost to complete these agreements was approximately $6,980,000 . All of these agreements may be terminated by either party upon appropriate notice as stipulated in the respective agreements. b) On June 22, 2009, the Company entered into a License Agreement with Korea Research Institute of Chemical Technology (“KRICT”) to acquire the rights to all intellectual property related to quinoxaline-piperazine derivatives that were synthesized under a Joint Research Agreement. The initial license fee was $ 100,000 , all of which was paid as of December 31, 2009. The agreement with KRICT calls for a one-time milestone payment of $ 1,000,000 within 30 days after the first achievement of marketing approval of the first commercial product arising out of or in connection with the use of KRICT’s intellectual property. As of September 30, 2018, the milestone has not occurred. c) Office Space Lease On June 5, 2009, the Company entered into a commercial lease agreement for 5,466 square feet of office space in Rockville, Maryland. The lease was amended on June 7, 2013 to extend the term until June 30, 2019. On July 26, 2014 the lease was amended to add 1,727 square feet of office space for a term beginning on September 1, 2014 and ending on August 31, 2015. The lease of additional space was subsequently renewed through June 30, 2019. Under the lease agreement, the Company pays its allocable portion of real estate taxes and common area operating charges. Rent paid under the Company’s lease during the three months ended September 30, 2018 and 2017 was $ 53,850 and $5 2,172 , respectively, and rent paid during the nine months ended September 30, 2018 and 2017 was $1 59,247 and $1 53,968 respectively. Laboratory Lease On April 20, 2015, the Company signed a five -year lease agreement for 2,552 square feet of laboratory space commencing on July 1, 2015 and ending on June 30, 2020. Under the lease agreement, the Company pays its allocable portion of real estate taxes and common area operating charges. Rent paid under this lease during the three months ended September 30, 2018 and 2017 was $ 16,732 and $ 16,244 , respectively, and rent paid during the nine months ended September 30, 2018 and 2017 was $49,221 and $47,787 , respectively. Future rental payments over the next five years for all leases are as follows:    For the remaining three months ending December 31: 2018 $ 70,806  For the year ending December 31: 2019 176,080  2020 34,468   Total $ 281,354   d) The Company has established a 401(k) plan for its employees. The Company has elected to match 100% of the first 3% of an employee’s compensation plus 50% of an additional 2% of the employee’s deferral. Expense related to this matching contribution aggregated to $ 29,425 and $3 1,453 for the three months ended September 30, 2018 and 2017, respectively, and $ 99,702 and $ 92,203 for the nine months ended September 30, 2018 and 2017, respectively. e) In July 2013, the Company entered into an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer Drug Conjugate Systems. As of September 30, 2018, no development milestones have occurred. f) In October 2013, the Company signed an exclusive license agreement with the Ohio State Innovation Foundation, for a novel oligonucleotide drug delivery platform, Lipid-Coated Albumin Nanoparticle. The agreement requires the Company to make payments to the Ohio State Innovation Foundation if any products from the licensed delivery platform achieve development milestones. As of September 30, 2018, no development milestones have occurred. g) On February 5, 2018, the Company and Next BT terminated the research collaboration agreement between the Company and Rexgene. In exchange for Next BT terminating its rights to RX-0201 in Asia, the Company agreed to pay Next BT a royalty in the low single digits of any net sales of RX-0201 the Company makes in Asia and 50% of the Company’s licensing revenue related to licensing of RX-0201 in Asia, up to an aggregate of $5,000,000 . 

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Measurements [Abstract]
Fair Value Measurements	15. Fair Value Measurements ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).  The three levels are described below:  Level 1 Inputs — Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible by the Company; Level 2 Inputs — Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and Level 3 Inputs — Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants. The following tables present assets and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. There have been no changes in the methodologies used at September 30, 2018 and December 31, 2017. de    Fair Value Measurements at September 30, 2018  Total Level 1 Level 2 Level 3  Assets:  Corporate Bonds $ 7,974,010 $ - $ 7,974,010 $ -   Liabilities:  Warrant Liabilities $ 4,101,504 $ - $ - $ 4,101,504     Fair Value Measurements at December 31, 2017  Total Level 1 Level 2 Level 3  Assets:  Commercial Paper 3,238,500 - 3,238,500 -  Corporate Bonds 14,693,441 - 14,693,441 -  Total Assets: $ 17,931,941 $ - $ 17,931,941 $ -   Liabilities:  Warrant Liabilities $ 7,853,635 $ - $ - $ 7,853,635  The fair value of the Company’s Level 2 marketable securities is determined by using quoted prices from independent pricing services that use market data for comparable securities in active or inactive markets. A variety of data inputs, including benchmark yields, interest rates, known historical trades and broker dealer quotes are used with pricing models to determine the quoted prices.  The fair value methodology for the warrant liabilities is disclosed in Note 12.  The carrying amounts reported in the financial statements for cash and cash equivalents (Level 1), and accounts payable and accrued expenses approximate fair value because of the short-term maturity of these financial instruments.  The following table sets forth a reconciliation of changes for the nine months ended September 30, 2018 and 2017 in the fair value of the liabilities classified as Level 3 in the fair value hierarchy:      Warrant Liabilities  Balance at January 1, 2018 $ 7,853,635  Additions -  Unrealized gains, net (3,752,131)  Transfers out of level 3 -  Balance at September 30, 2018 $ 4,101,504     Warrant Liabilities  Balance at January 1, 2017 $ 1,573,366  Additions 4,107,488  Unrealized losses, net 9,047,831  Transfers out of level 3 (8,052,594)  Balance at September 30, 2017 $ 6,676,091 Additions consist of the fair value of warrant liabilities upon issuance. Transfers out of Level 3 for warrant liabilities consist of warrant exercises, where the liability is converted to additional paid-in capital upon exercise. The Company’s policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstance that caused the transfer.

Collaboration Agreement

Collaboration Agreement	9 Months Ended
	Sep. 30, 2018
Collaboration Agreement [Abstract]
Collaboration Agreement	16. Collaboration Agreement  On August 16, 2018, the Company entered into a clinical trial collaboration and supply agreement (the “Collaboration Agreement”) with Merck Sharp & Dohme B.V. (“Merck”) to conduct a Phase 2 clinical trial to evaluate the safety and efficacy of the combination of RX-5902 with Merck’s anti-PD ‑1 therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple negative breast cancer (TNBC). Under the terms of the Collaboration Agreement, the Company will sponsor the clinical trial and Merck will supply the Company with KEYTRUDA for use in the trial at no cost to the Company . The Collaboration Agreement provides that the Company and Merck will jointly own clinical data generated from the clinical trial. 

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Event  On October 19, 2018, the Company closed a registered direct offering of 5,769,231 shares of common stock and warrants to purchase up to 5,769,231 shares of common stock, resulting in gross proceeds to the Company of approximately $7,500,000 . The common stock and warrants were sold in units, consisting of a share of common stock and a warrant to purchase a share of common stock, at a price of $1.30 per unit, with an exercise price for the warrants of $1.67 per share . The warrants will become exercisable April 19, 2019 and will remain exercisable through April 19, 2024. The Company also issued warrants to purchase up to 346,154 shares of the Company’s common stock, at an exercise price of $1.625 per share, to designees of the placement agent in the offering. 

Operations And Organization (Po

Operations And Organization (Policies)	9 Months Ended
	Sep. 30, 2018
Operations And Organization [Abstract]
Operations	Operations Rexahn Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biopharmaceutical company whose principal operations are the discovery and development of innovative treatments for cancer.
Liquidity And Going Concern	Liquidity and Going Concern Accounting Standards Codification (“ASC”) 205-40 , Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASC 205-40”) , requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.  As of September 30, 2018, the Company had cash, cash equivalents and marketable securities of approximately $12.6 million, working capital of approximately $10. 4 million and an accumulated deficit of approximately $151. 6 million, and anticipates incurring losses through fiscal year 2018 and beyond. The Company has incurred negative cash flow from operations since inception and not yet generated commercial revenues. The Company believes that its cash, cash equivalents, and marketable s ecurities at September 30, 2018 and the proceeds received from its completed registered direct public offering in October 2018, will be sufficient to fund current operations through the third quarter of 2019 and that the Company would require additional capital to fund operations beyond that point. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements are issued. To meet its needs, the Company intends to raise additional capital through equity financings, collaborations, or partnerships. Under ASC 205-40 , management’s plans must be approved before the date the financial statements are issued to be considered probable of being effectively implemented, and the future receipt of potential funding is not considered probable at this time because none of the Company’s current plans have been finalized at the time of filing this Quarterly Report on Form 10-Q. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued.
Basis Of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of September 30, 2018 and December 31, 2017 and of the results of operations, and comprehensive loss for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017 have been included. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of results that may be expected for any other interim period or the full fiscal year ending December 31, 2018. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Form 10-K”). Information included in the condensed balance sheet as of December 31, 2017 has been derived from the Company’s audited financial statements for the year ended December 31, 2017 included in the 2017 Form 10-K. The unaudited condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. 
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Actual results may ultimately differ from these estimates. These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available.

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements Affecting the Company (Policies)	9 Months Ended
	Sep. 30, 2018
Recent Accounting Pronouncements Affecting the Company [Abstract]
Recent Accounting Pronouncements Affecting the Company	Revenue from Contracts with Customers  In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers,” a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company should recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services and provides a revenue recognition framework in accordance with this principle. On August 12, 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 by one year to December 15, 2017 for annual reporting periods beginning after that date and interim periods therein. The Company adopted this guidance for the quarterly reporting period ended March 31, 2018, using the modified retrospective method. As the Company does not have revenue contracts, the adoption of this guidance did not have a material impact on the operating results of the Company, there were no significant changes to disclosures, and there was no cumulative adjustment to the opening balance of retained earnings as of January 1, 2018.  Leases  In February 2016, the FASB issued ASU 2016-02, “Leases,” which requires an entity to recognize assets and liabilities arising from leases on the balance sheet and to provide additional disclosures about leasing arrangements. ASU 2016-02 will be effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact the adoption of this guidance will have on its financial statements. 

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2018
Marketable Securities [Abstract]
Schedule Of Cost And Fair Value Of Marketable Securities	  September 30, 2018  Cost Gross Unrealized Gross Unrealized Fair  Basis Gains Losses Value  Corporate Bonds $ 8,003,497 $ - $ (29,487) $ 7,974,010   December 31, 2017  Cost Gross Unrealized Gross Unrealized Fair  Basis Gains Losses Value  Commercial Paper $ 3,241,005 $ - $ (2,505) $ 3,238,500  Corporate Bonds 14,747,822 - (54,381) 14,693,441  Total Marketable Securities $ 17,988,827 $ - $ (56,886) $ 17,931,941 

Prepaid Expenses And Other Cu_2

Prepaid Expenses And Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Prepaid Expenses And Other Current Assets [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets	   September 30, December 31,  2018 2017   Deposits on contracts $ 520,677 $ 793,940  Prepaid expenses and other current assets 634,221 510,601   $ 1,154,898 $ 1,304,541 

Equipment, Net (Tables)

Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2018
Equipment, Net [Abstract]
Schedule Of Equipment, Net	   September 30, December 31,  2018 2017   Furniture and fixtures $ 82,686 $ 82,686  Office and computer equipment 159,489 171,724  Lab equipment 447,653 445,134  Leasehold improvements 131,762 133,762   Total equipment 821,590 833,306  Less: Accumulated depreciation and amortization (698,110) (711,846)   Net carrying amount $ 123,480 $ 121,460 

Accounts Payable And Accrued _2

Accounts Payable And Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Accounts Payable And Accrued Expenses [Abstract]
Schedule Of Accounts Payable And Accrued Expenses	   September 30, December 31,  2018 2017   Trade payables $ 1,298,168 $ 895,638  Accrued expenses 103,000 95,416  Accrued research and development contract costs 1,252,445 1,435,109  Payroll liabilities 678,033 807,763   $ 3,331,646 $ 3,233,926 

Other Liabilities (Tables)

Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Other Liabilities [Abstract]
Schedule Of Deferred Lease Incentive	   September 30, December 31,  2018 2017   Deferred lease incentive $ 154,660 $ 154,660  Less accumulated amortization (145,327) (135,995)   Balance $ 9,333 $ 18,665 

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Stock-Based Compensation [Abstract]
Summary Of Stock Compensation Expense	  For the Three Months Ended September 30, For the Nine Months Ended September 30,  2018 2017 2018 2017  Statement of operations line item:  General and administrative $ 188,920 $ 184,914 $ 579,924 $ 580,812  Research and development 92,562 42,700 265,286 209,194   Total $ 281,482 $ 227,614 $ 845,210 $ 790,006 
Schedule Of Assumptions Made In Calculating The Fair Value Of Options	   Nine Months Ended September 30,  2018 2017  Black-Scholes assumptions  Expected dividend yield 0 % 0 %  Expected volatility 69-72 % 69-79 %  Risk-free interest rate 2.3 -2.8 % 1.8 -2.0 %  Expected term (in years) 5.5 -6 years 5.5 -6 years 
Summary Of Share-Based Transactions	   Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value  Outstanding, January 1, 2018 1,814,231 $ 5.33 7.1 years $ 53,883  Granted 860,307 $ 1.96  Exercised - $ -  Expired (25,000) $ 21.78  Cancelled (50,500) $ 5.16   Outstanding, September 30, 2018 2,599,038 $ 4.06 7.5 years $ 50,870  Exercisable, September 30, 2018 1,345,721 $ 5.71 6.1 years $ - 
Summary Of Unvested Shares	   2018  Number of Options Weighted Average Fair Value at Grant Date  Unvested at January 1, 2018 727,543 $ 2.39  Granted 860,307 $ 1.27  Vested (334,533) $ 2.89  Cancelled - $ -   Unvested at September 30, 2018 1,253,317 $ 1.49 
Summary Of RSU Activity	  Number of RSUs Weighted Average Grant Date Fair Value  Outstanding, January 1, 2018 47,300 $ 1.84  Granted - $ -  Vested and Released (11,825) $ 1.84  Cancelled - $ -   Outstanding, September 30, 2018 35,475 $ 1.84 

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2018
Warrants [Abstract]
Summary Of Changes In Warrants Outstanding During The Period	   2018 2017  Number of warrants Weighted average exercise price Number of warrants Weighted average exercise price  Balance, January 1 7,099,609 $ 4.55 5,452,691 $ 4.92  Issued during the period - $ - 1,696,970 $ 4.01  Exercised during the period - $ - (1,861,195) $ 3.51  Expired during the period (200,000) $ 5.90 - $ -   Balance, September 30 6,899,609 $ 4.51 5,288,466 $ 5.13 
Schedule Of Fair Value Of Warrants Issued	   Fair Value as of:  Warrant Issuance: September 30, 2018 December 31, 2017  July 2013 Investor Warrants $ - $ 8,762  October 2013 Investor Warrants - 26,288  January 2014 Investor Warrants - 29,257  November 2015 Investor Warrants 399,278 1,260,050  November 2015 Placement Agent Warrants 591 2,936  March 2016 Investor Warrants 296,462 697,554  September 2016 Investor Warrants 592,513 1,054,083  June 2017 Investor Warrants 1,059,522 1,981,864  June 2017 Placement Agent Warrants 115,769 221,591  October 2017 Investor Warrants 1,476,646 2,305,552  October 2017 Placement Agent Warrants 160,723 265,698  Total: $ 4,101,504 $ 7,853,635 
Summary Of Shares Indexed To The Warrants	   Number of Shares indexed as of:  Warrant Issuance September 30, 2018 December 31, 2017  July 2013 Investor Warrants - 200,000  October 2013 Investor Warrants 231,732 231,732  January 2014 Investor Warrants 476,193 476,193  November 2015 Investor Warrants 1,250,001 1,250,001  November 2015 Placement Agent Warrants 3,334 3,334  March 2016 Investor Warrants 607,806 607,806  September 2016 Investor Warrants 805,000 805,000  June 2017 Investor Warrants 1,515,152 1,515,152  June 2017 Placement Agent Warrants 181,818 181,818  October 2017 Investor Warrants 1,632,654 1,632,654  October 2017 Placement Agent Warrants 195,919 195,919  Total: 6,899,609 7,099,609 
Schedule Of Assumptions Used In Calculating Fair Value Of Warrants	   September 30, 2018 December 31, 2017  Trading market prices $ 1.78 $ 2.02  Estimated future volatility 101 % 104 %  Dividend - -  Estimated future risk-free rate 3.02 -3.04 % 2.14 -2.45 %  Equivalent volatility 49-76 % 85-104 %  Equivalent risk-free rate 1.10 -2.70 % 1.30 -1.89 % 
Schedule Of Unrealized Gain/(Loss) On Fair Value Of Warrants	  For the Three Months Ended September 30, For the Nine Months Ended September 30,  2018 2017 2018 2017  Expired and Fully Exercised Warrants $ - $ 7,306 $ - $ (855,010)  July 2013 Investor Warrants - 125,686 8,762 (55,362)  October 2013 Investor Warrants - 135,683 26,288 (102,608)  January 2014 Investor Warrants - 177,900 29,257 (125,148)  November 2015 Investor Warrants 5,971 797,688 860,772 (1,304,350)  November 2015 Placement Agent Warrants 211 1,691 2,345 (366,694)  March 2016 Investor Warrants (38,943) 356,472 401,092 (2,873,309)  September 2016 Investor Warrants (109,915) 506,353 461,570 (4,807,246)  June 2017 Investor Warrants (178,869) 894,076 922,342 1,277,485  June 2017 Placement Agent Warrants (22,518) 117,645 105,822 164,411  October 2017 Investor Warrants (331,671) - 828,906 -  October 2017 Placement Agent Warrants (34,331) - 104,975 -  Total: $ (710,065) $ 3,120,500 $ 3,752,131 $ (9,047,831) 

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2018
Income Taxes [Abstract]
Schedule Of Deferred Tax Assets And Valuation Allowance	   September 30, December 31,  2018 2017   Net Operating Loss Carryforwards $ 39,897,000 $ 35,805,000  Stock Compensation Expense 1,558,000 1,458,000  Book tax differences on assets and liabilities 209,000 365,000  Valuation Allowance (41,664,000) (37,628,000)   Net Deferred Tax Assets $ - $ - 

Commitments And Contingencies (

Commitments And Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies [Abstract]
Schedule Of Future Rental Payments	   For the remaining three months ending December 31: 2018 $ 70,806  For the year ending December 31: 2019 176,080  2020 34,468   Total $ 281,354 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Measurements [Abstract]
Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis	   Fair Value Measurements at September 30, 2018  Total Level 1 Level 2 Level 3  Assets:  Corporate Bonds $ 7,974,010 $ - $ 7,974,010 $ -   Liabilities:  Warrant Liabilities $ 4,101,504 $ - $ - $ 4,101,504     Fair Value Measurements at December 31, 2017  Total Level 1 Level 2 Level 3  Assets:  Commercial Paper 3,238,500 - 3,238,500 -  Corporate Bonds 14,693,441 - 14,693,441 -  Total Assets: $ 17,931,941 $ - $ 17,931,941 $ -   Liabilities:  Warrant Liabilities $ 7,853,635 $ - $ - $ 7,853,635 
Reconciliation Of Changes In The Fair Value Of Liabilities	   Warrant Liabilities  Balance at January 1, 2018 $ 7,853,635  Additions -  Unrealized gains, net (3,752,131)  Transfers out of level 3 -  Balance at September 30, 2018 $ 4,101,504     Warrant Liabilities  Balance at January 1, 2017 $ 1,573,366  Additions 4,107,488  Unrealized losses, net 9,047,831  Transfers out of level 3 (8,052,594)  Balance at September 30, 2017 $ 6,676,091 

Operations And Organization (De

Operations And Organization (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Operations And Organization [Abstract]
Cash, cash equivalents and marketable securities	$ 12,600,000
Working Capital	10,400,000
Accumulated deficit	$ 151,570,672	$ 140,318,712

Marketable Securities (Narrativ

Marketable Securities (Narrative) (Details) - Corporate Bonds [Member]	Sep. 30, 2018USD ($)item
Schedule of Available-for-sale Securities [Line Items]
Securities in a loss position, less than one year | item	6
Fair value, less than one year	$ 5,974,460
Unrealized losses, less than one year	$ 26,899
Securities in a loss position, greater than one year | item	2
Fair value, greater than one year	$ 1,999,550
Unrealized losses, greater than one year	$ 2,588

Marketable Securities (Schedule

Marketable Securities (Schedule Of Cost And Fair Value Of Marketable Securities) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Cost Basis		$ 17,988,827
Gross Unrealized Losses		(56,886)
Fair Value		17,931,941
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost Basis		3,241,005
Gross Unrealized Losses		(2,505)
Fair Value		3,238,500
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost Basis	$ 8,003,497	14,747,822
Gross Unrealized Losses	(29,487)	(54,381)
Fair Value	$ 7,974,010	$ 14,693,441

Prepaid Expenses And Other Cu_3

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Prepaid Expenses And Other Current Assets [Abstract]
Deposits on contracts	$ 520,677	$ 793,940
Prepaid expenses and other current assets	634,221	510,601
Total prepaid expenses and other current assets	$ 1,154,898	$ 1,304,541

Equipment, Net (Details)

Equipment, Net (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total equipment	$ 821,590	$ 833,306
Less: Accumulated depreciation and amortization	(698,110)	(711,846)
Net carrying amount	123,480	121,460
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total equipment	82,686	82,686
Office And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total equipment	159,489	171,724
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Total equipment	447,653	445,134
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total equipment	$ 131,762	$ 133,762

Accounts Payable And Accrued _3

Accounts Payable And Accrued Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts Payable And Accrued Expenses [Abstract]
Trade payables	$ 1,298,168	$ 895,638
Accrued expenses	103,000	95,416
Accrued research and development contract costs	1,252,445	1,435,109
Payroll liabilities	678,033	807,763
Total accounts payable and accrued expenses	$ 3,331,646	$ 3,233,926

Deferred Research And Develop_2

Deferred Research And Development Arrangement (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2003	Feb. 05, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Other income		$ 368,750
Percentage of licensing revenue					50.00%
Rexgene Biotech Co., Ltd. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development arrangement, one-time fee				$ 1,500,000
Reduction of research and development expenses	$ 18,750	$ 6,250	$ 56,250
Research and development period		20 years
Other income		$ 368,750
Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Licensing revenue agreement					$ 5,000,000

Other Liabilities (Narrative) (

Other Liabilities (Narrative) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Other Liabilities [Abstract]
Accrued Rent	$ 20,517	$ 38,059

Other Liabilities (Schedule Of

Other Liabilities (Schedule Of Deferred Lease Incentive) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Other Liabilities [Abstract]
Deferred lease incentive	$ 154,660	$ 154,660
Less accumulated amortization	(145,327)	(135,995)
Balance	$ 9,333	$ 18,665

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Stock Options, Restricted Stock Units And Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	9,534,122	8,961,140

Common Stock (Details)

Common Stock (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Aug. 30, 2018	Dec. 31, 2017
Common Stock [Abstract]
Common Stock, Shares Authorized	75,000,000	75,000,000	50,000,000
Stock issued for services	15,000
Aggregate market value	$ 22,650
Restricted stock issued	11,825

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($)	Apr. 11, 2017	Mar. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jun. 10, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Income tax benefit from share-based compensation					$ 0
Valuation allowance on deferred tax assets					100.00%
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding			2,599,038		2,599,038		1,814,231
Stock options granted					860,307
Stock option exercise price					$ 1.96
Intrinsic value of options exercised			$ 0	$ 0	$ 0	$ 97,872
Options exercised
Weighted average fair value at grant date, Vested					$ 1.27	$ 1.53
Unrecognized compensation cost			$ 1,494,158		$ 1,494,158
Weighted average vesting period, years					2 years 6 months
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of RSUs outstanding			35,475		35,475		47,300
Unrecognized compensation cost			$ 51,512		$ 51,512
Weighted average vesting period, years					2 years 4 months 24 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options authorized for issuance								1,700,000
Additional options authorized for issuance	1,700,000
Shares available for issuance			1,064,912		1,064,912
The 2013 Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding			2,287,038		2,287,038
The 2013 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of RSUs outstanding			35,475		35,475
The 2003 Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding			300,000		300,000
Share-based Compensation Award, Tranche One [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage					25.00%
Share-based Compensation Award, Tranche Two [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage					2.78%
Maximum [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration of options from grant date, years					10 years
Exercise Price Range $1.46 to $2.29 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted					860,307
Stock option grants fair value					$ 1,089,851
Exercise Price Range $1.46 to $2.29 [Member] | Minimum [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercise price					$ 1.46
Exercise Price Range $1.46 to $2.29 [Member] | Maximum [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercise price					$ 2.29
Exercise Price Range $1.84 to $6.18 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted						483,260
Stock option grants fair value						$ 738,937
Exercise Price Range $1.84 to $6.18 [Member] | Minimum [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercise price						$ 1.84
Exercise Price Range $1.84 to $6.18 [Member] | Maximum [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercise price						$ 6.18
Non-Employee Transaction [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of Event Occurence to Vest					100.00%
Non-Employee Transaction [Member] | Minimum [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					1 year
Non-Employee Transaction [Member] | Maximum [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					3 years
Third Party [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		12,000

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary Of Stock Compensation Expense) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share Based Compensation	$ 281,482	$ 227,614	$ 845,210	$ 790,006
General and administrative [Member]
Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share Based Compensation	188,920	184,914	579,924	580,812
Research and development [Member]
Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share Based Compensation	$ 92,562	$ 42,700	$ 265,286	$ 209,194

Stock-Based Compensation (Sched

Stock-Based Compensation (Schedule Of Assumptions Made In Calculating The Fair Value Of Options) (Details) - Stock Option [Member]	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Expected volatility, minimum	69.00%	69.00%
Expected volatility, maximum	72.00%	79.00%
Risk free interest rate, minimum	2.30%	1.80%
Risk free interest rate, maximum	2.80%	2.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 6 months	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years	6 years

Stock-Based Compensation (Sum_2

Stock-Based Compensation (Summary Of Share-Based Transactions ) (Details) - Stock Option [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Number of Options, Oustanding	1,814,231
Number of Options, Granted	860,307
Number of Options, Exercised
Number of Options, Expired	(25,000)
Number of Options, Cancelled	(50,500)
Number of Options, Oustanding	2,599,038	1,814,231
Weighted Average Exercise Price, Outstanding	$ 5.33
Weighted Average Exercise Price, Granted	1.96
Weighted Average Exercise Price, Exercised
Weighted average exercise price, Expired	21.78
Weighted Average Exercise Price, Cancelled	5.16
Weighted Average Exercise Price, Outstanding	$ 4.06	$ 5.33
Weighted Average Remaining Contractual Term, Outstanding	7 years 6 months	7 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	$ 50,870	$ 53,883
Number of Options, Exercisable	1,345,721
Weighted Average Exercise Price, Exercisable	$ 5.71
Weighted Average Remaining Contractual Term, Exercisable	6 years 1 month 6 days
Aggregate Intrinsic Value, Exercisable

Stock-Based Compensation (Sum_3

Stock-Based Compensation (Summary Of Unvested Shares) (Details) - Stock Option [Member]	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of Options, Unvested | shares	727,543
Number of Options, Granted | shares	860,307
Number of Options, Vested | shares	(334,533)
Number of Options, Cancelled | shares
Number of Options, Unvested | shares	1,253,317
Weighted Average Fair Value at Grant Date, Unvested | $ / shares	$ 2.39
Weighted Average Fair Value at Grant Date, Granted | $ / shares	1.27
Weighted Average Fair Value at Grant Date, Vested | $ / shares	2.89
Weighted Average Fair Value at Grant Date, Cancelled | $ / shares
Weighted Average Fair Value at Grant Date, Unvested | $ / shares	$ 1.49

Stock-Based Compensation (Sum_4

Stock-Based Compensation (Summary Of RSU Activity) (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of RSUs, Outstanding | shares	47,300
Number of RSUs, Granted | shares
Number of RSUs, Vested and Released | shares	(11,825)
Number of RSUs, Cancelled | shares
Number of RSUs, Outstanding | shares	35,475
Weighted Average Grant Date Fair Value, Outstanding | $ / shares	$ 1.84
Weighted Average Grant Date Fair Value, Granted | $ / shares
Weighted Average Grant Date Fair Value, Vested and Released | $ / shares	1.84
Weighted Average Grant Date Fair Value, Cancelled | $ / shares
Weighted Average Grant Date Fair Value, Outstanding | $ / shares	$ 1.84

Warrants (Narrative) (Details)

Warrants (Narrative) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Number of warrants, Outstanding	6,899,609	7,099,609	5,288,466	5,452,691
Warrant expiration date, start	Oct. 16, 2018
Warrant expiration date, end	Apr. 17, 2023
Average remaining contractual life of warrants outstanding	3 years 4 months 24 days
Probability of entering into a fundamental transaction	5.00%
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price	$ 12.80
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price	$ 2.85

Warrants (Summary Of Changes In

Warrants (Summary Of Changes In Warrants Outstanding During The Period) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Warrants [Abstract]
Number of warrants, Outstanding	7,099,609	5,452,691
Weigted average exercise price, Outstanding	$ 4.55	$ 4.92
Number of warrants, issued		1,696,970
Weighted average exercise price, Issued		$ 4.01
Number of warrants, Exercised		(1,861,195)
Weighted average exercise price, Exercised		$ 3.51
Number of warrants, Expired	(200,000)
Weighted average exercise price, Expired	$ 5.90
Number of warrants, Outstanding	6,899,609	5,288,466
Weigted average exercise price, Outstanding	$ 4.51	$ 5.13

Warrants (Schedule Of Fair Valu

Warrants (Schedule Of Fair Value Of Warrants Issued) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Fair value	$ 4,101,504	$ 7,853,635
July 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value		8,762
October 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value		26,288
January 2014 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value		29,257
November 2015 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	399,278	1,260,050
November 2015 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	591	2,936
March 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	296,462	697,554
September 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	592,513	1,054,083
June 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	1,059,522	1,981,864
June 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	115,769	221,591
October 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	1,476,646	2,305,552
October 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value	$ 160,723	$ 265,698

Warrants (Summary Of Shares Ind

Warrants (Summary Of Shares Indexed To The Warrants) (Details) - shares	Sep. 30, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Number of shares indexed	6,899,609	7,099,609
July 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed		200,000
October 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	231,732	231,732
January 2014 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	476,193	476,193
November 2015 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	1,250,001	1,250,001
November 2015 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	3,334	3,334
March 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	607,806	607,806
September 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	805,000	805,000
June 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	1,515,152	1,515,152
June 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	181,818	181,818
October 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	1,632,654	1,632,654
October 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Number of shares indexed	195,919	195,919

Warrants (Schedule Of Assumptio

Warrants (Schedule Of Assumptions Used In Calculating Fair Value Of Warrants) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Trading market prices	$ 1.78	$ 2.02
Estimated future volatility	101.00%	104.00%
Dividend
Minimum [Member]
Class of Warrant or Right [Line Items]
Estimated future risk-free rate	3.02%	2.14%
Equivalent volatility	49.00%	85.00%
Equivalent risk-free rate	1.10%	1.30%
Maximum [Member]
Class of Warrant or Right [Line Items]
Estimated future risk-free rate	3.04%	2.45%
Equivalent volatility	76.00%	104.00%
Equivalent risk-free rate	2.70%	1.89%

Warrants (Schedule Of Unrealize

Warrants (Schedule Of Unrealized Gain/(Loss) On Fair Value Of Warrants) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	$ (710,065)	$ 3,120,500	$ 3,752,131	$ (9,047,831)
Expired And Fully Exercised Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants		7,306		(855,010)
July 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants		125,686	8,762	(55,362)
October 2013 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants		135,683	26,288	(102,608)
January 2014 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants		177,900	29,257	(125,148)
November 2015 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	5,971	797,688	860,772	(1,304,350)
November 2015 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	211	1,691	2,345	(366,694)
March 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(38,943)	356,472	401,092	(2,873,309)
September 2016 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(109,915)	506,353	461,570	(4,807,246)
June 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(178,869)	894,076	922,342	1,277,485
June 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(22,518)	$ 117,645	105,822	$ 164,411
October 2017 Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	(331,671)		828,906
October 2017 Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Unrealized (loss) gain on fair value of warrants	$ (34,331)		$ 104,975

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Provision for income taxes
Operating loss carry-forward	142,488,000		142,488,000		$ 127,877,000
Federal And State [Member]
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 0		$ 0

Income Taxes (Schedule Of Defer

Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Income Taxes [Abstract]
Net Operating Loss Carryforwards	$ 39,897,000	$ 35,805,000
Stock Compensation Expense	1,558,000	1,458,000
Book tax differences on assets and liabilities	209,000	365,000
Valuation Allowance	(41,664,000)	(37,628,000)
Net Deferred Tax Assets

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)	Apr. 20, 2015ft²	Jul. 26, 2014ft²	Jun. 07, 2013ft²	Jun. 22, 2009USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2009USD ($)	Feb. 05, 2018USD ($)
Commitments And Contingencies [Line Items]
Estimated cost to complete contracts					$ 6,980,000		$ 6,980,000
License Costs									$ 100,000
One-time milestone payment				$ 1,000,000
Employer matching contribution							100.00%
Maximum percentage of employee's gross pay							3.00%
Employer matching contribution on deferral							50.00%
Percentage of employee's gross pay							2.00%
Expense related to matching contribution					$ 29,425	$ 31,453	$ 99,702	$ 92,203
Percentage of licensing revenue										50.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Contract term, months							36 months
Licensing revenue agreement										$ 5,000,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Contract term, months							2 months
Current Laboratory Lease [Member]
Commitments And Contingencies [Line Items]
Lease term					5 years		5 years
Size of lease space | ft²	2,552
Rent expense					$ 16,732	16,244	$ 49,221	47,787
Office Space Rental [Member]
Commitments And Contingencies [Line Items]
Size of lease space | ft²			5,466
Additional office space | ft²		1,727
Rent expense					$ 53,850	$ 52,172	$ 159,247	$ 153,968

Commitments and Contingencies_3

Commitments and Contingencies (Schedule Of Future Rental Payments) (Details)	Sep. 30, 2018USD ($)
Commitments And Contingencies [Abstract]
2,018	$ 70,806
2,019	176,080
2,020	34,468
Total	$ 281,354

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		$ 17,931,941
Warrant Liabilities	$ 4,101,504	7,853,635
Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:	7,974,010	14,693,441
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		3,238,500
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		17,931,941
Level 2 [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:	7,974,010	14,693,441
Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets:		3,238,500
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liabilities	$ 4,101,504	$ 7,853,635

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation Of Changes In The Fair Value Of Liabilities) (Details) - Warrant Liabilities [Member] - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 7,853,635	$ 1,573,366
Additions		4,107,488
Unrealized (gains) losses, net	(3,752,131)	9,047,831
Transfers out of level 3		(8,052,594)
Balance	$ 4,101,504	$ 6,676,091

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Oct. 19, 2018	Sep. 30, 2018	Sep. 30, 2017
Subsequent Event [Line Items]
Number of warrants, issued			1,696,970
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued	5,769,231
Number of warrants, issued	5,769,231
Share Price	$ 1.30
Stock Warrants, Exercise Price	$ 1.67
Proceeds from issuance	$ 7,500,000
Warrants issued to placement agent	346,154
Placement agent, share price	$ 1.625